While dose escalation is proving important to achieve satisfactory long-term outcomes in prostate cancer, the optimal radiation modality to deliver the treatment is still a topic of debate. Charged particle beams can offer improved dose distributions to the target volume as compared to conventional 3D-conformal radiotherapy, with better sparing of surrounding healthy tissues. Exquisite dose distributions, with the fulfillment of dose-volume constraints to normal tissues, however, can also be achieved with photon-based intensity-modulated techniques. This review summarizes the literature on the use of particle therapy in prostate cancer and attempts to put in perspective its relative merits compared to current photon-based radiotherapy.
Introduction
One of the most important observations with the use of modern radiotherapy techniques for prostate cancer is the recognition of a clear dose-response relationship. Clinical dose-escalation studies, both retrospective and randomized, have corroborated this notion. [1] [2] [3] [4] [5] [6] [7] [8] The optimal dose with regard to local tumor control and normal tissue tolerance in the treatment of adenocarcinoma of the prostate, however, remains unclear. Statistically significant improvements with dose escalation in terms of freedom from biochemical failure (bNED) have already been shown by two randomized studies using photons 2 or combined photons and proton boost. 5 Whether these improvements will eventually translate into increased overall survival is still a matter of scientific speculation. 8, 9 The radiation therapy oncology group (RTOG) is currently conducting a phase III randomized trial (P-0126) comparing high-dose (82.2 Gy in 44 fractions) to standard dose (72.9 Gy in 39 fractions) with the aim to demonstrate a survival advantage in men treated at higher dose. A previous RTOG study had shown a low incidence of late radiation-induced morbidity up to dose levels of 78 Gy with current X-ray techniques. 10 Several clinical trials are currently underway with the aim to better define the role of dose escalation in prostate cancer. 11, 12 The optimal modality to deliver high-dose irradiation to the prostate and seminal vesicles is a matter of debate in the literature. Intensity-modulated radiotherapy (IMRT) represents the most sophisticated form of X-ray irradiation and has been shown to be an effective tool for safe dose escalation in prostate cancer. 3, 13, 14 Some have raised concerns that the increased integral doses to surrounding normal tissues subsequent to IMRT delivery may elevate the risk of induced secondary malignancy development. 15, 16 This is still a rather controversial issue which will be addressed in more detail in the section on radiation-induced carcinogenesis below.
With the aim to optimize the therapeutic ratio, in lieu of external beam X-ray irradiation, various treatment modalities have been advocated, including particle therapy and brachytherapy, both in the form of permanent seed implants 17 or high dose rate 18 temporary implants, either alone or in conjunction with external beam irradiation.
The aim of this article is to review the literature on particle therapy in prostate cancer to shed some light on the current controversies surrounding their potential benefits over photon-based IMRT and whether the additional costs of these therapeutic modalities are justified.
The results of some current series of photon-based IMRT, protons and carbon ions with homogeneous outcome and toxicity definitions are summarized in Table 1 .
Physical and radiobiological characteristics of particles
Particle therapy may be broadly divided into charged particles (protons and light ions) and neutrons. Charged particles have a finite range in tissues. As they lose velocity traversing through tissues, the interactions with matter that causes ionizations increase, so that a peak of dose occurs at a depth proportional to the energy of each particle. Beyond this peak (known as Bragg peak) no further dose deposition occurs. The dose peak may be 'spread out' to achieve a plateau of uniform dose to precisely cover the target while sparing adjacent normal structures (SOBP, spread-out Bragg peaks). Because of their lack of charge, neutrons display dose distributions, which do not significantly differ from those of X-rays and therefore lack the physical dose advantages of charged particles.
The dose delivered with particles is prescribed in gray equivalents (GyE) or cobalt gray equivalents (CGE) often used with protons. GyE and CGE are equal to the measured physical dose in gray multiplied by the relative biological effectiveness (RBE) factor specific for the beam used. The RBE is the ratio of dose of radiation required to produce a certain biological effect with photons relative to the dose required to produce the same effect with another form of ionizing radiation, such as protons and light ions. The RBE factor of a certain beam is a function of its linear energy transfer (LET), which is determined by the atomic number of the particles and the energy of the beam. Therefore, neutrons and light ions beams have higher LET than more sparsely ionizing radiation beams, such as photons, electrons and protons. An RBE value of 1.1 is generally accepted for clinical use with proton beams. The RBE of neutron and carbon ions is difficult to calculate and for dose-reporting purposes a value of 3 is often utilized. 24 There is extensive literature on the use of particles in the treatment of prostate cancer. There appears to be two distinct clinical advantages that particle beams could offer over traditional photon therapy. First, dose escalation, with more effective normal tissue sparing, may be more readily achieved with protons in light of their improved dose distributions and lower integral doses compared to X-rays. Second, through the use of particles with a higher RBE, namely neutrons and light ions, increased tumor control may be realized, especially for patients with locally advanced tumors. Carbon ion therapy attempts to capture the 'best of both worlds', by exploiting the benefits of improved dose distributions, due to the presence of a defined Bragg peak, and concomitantly taking advantage of their high RBE to increase the tumor control probability.
Protons
The Massachusetts General Hospital group was the first to report on the use of protons as a boost technique for locally advanced prostate cancer. In a phase I/II study an additional dose of 5-7 Gy with protons was delivered following standard pelvic irradiation. Despite the 10% increase in dose no increased morbidity was observed in this initial experience. 25 Therefore, a phase III randomized trial in locally advanced (T3-T4) prostate cancer followed, 26 comparing conventional dose vs high dose by means of a proton boost. After a four-field photon irradiation to 50.4 Gy, patients were randomized to receive either an additional 25.2 CGE by conformal proton-beam boost (total dose 75.6 CGE) or an additional 16.8 Gy photon boost (total dose 67.2 Gy). No concomitant or adjuvant endocrine therapy was given. The proton boost technique consisted of a perineal 160 MeV approach with patients treated in the lithotomy position. The fractionation scheme was 2.1 CGE delivered in four Abbreviations: AA, androgen ablation; ASTRO, American Society for Therapeutic Radiology and Oncology; bNED, freedom from biochemical failure; C-ion, carbon ions; 3D-CRT, three-dimensional conformal radiotherapy; GI, gastrointestinal; GU, genitourinary; IMRT, Intensity-modulated radiotherapy; NA, not applicable; RT, radiotherapy; RTOG, radiation therapy oncology group.
Particle therapy in prostate cancer C Greco sessions per week with a cumulative dose of 25.2 CGE. The boost was begun 7-14 days after completion of conventional irradiation so as to allow sufficient healing of radiation proctitis, thereby facilitating for the patients the insertion of a rectal Lucite probe for correct alignment of the proton beam. The perineal field was aligned with the aid of a gold seed inserted in the prostatic apex, and biplanar X-rays were taken before each session to assure correct positioning of the target.
No difference in overall survival, disease-free survival or local recurrence-free survival was found between the two groups. In a subgroup analysis, however, poorly differentiated tumors (GPS 9 or 10) had improved local control with 94 and 84% in the proton boost arm and 64 and 19% in the photon-only arm maintaining local control at 5 and 8 years, respectively. Toxicity, however, was significantly higher in the high-dose arm, likely due to the use of a single perineal boost field. In particular, the incidence of rectal bleeding was significantly higher in the proton boost arm (32 vs 12%, P ¼ 0.002). The actuarial incidence of urethral stricture at 8 years was also higher in the high-dose arm (19 vs 8%), although this difference was not statistically significant (P ¼ 0.07).
Despite the increased morbidity in the high-dose arm, this study was the first to show a significant clinical benefit with dose escalation in selected patient groups. A recent update from MGH 27 with a median follow-up of 13.1 years for patients receiving 77. 4 Gy by means of a 27 Gy boost in 11 fractions, reported an actuarial incidence of RTOG grade X2 gastrointestinal (GI) toxicity of 13% at 5 and 15 years. The actuarial incidences of grade X2 hematuria were 21 and 47% at 5 and 15 years, respectively. Grade 3 hematuria was observed in 3 and 8% of the patients at 5 and 15 years, respectively.
Loma Linda University 28 reported on their experience with proton beam in prostate cancer. Initially, patients were treated with a combined approach with a 30 CGE boost to the prostate and seminal vesicles in 15 fractions following 45 Gy of four-field three-dimensional conformal radiotherapy (3D-CRT) pelvic photon irradiation. In a second stage, patients with o15% risk of nodal involvement according to Partin nomograms were treated by protons alone. Proton treatments consisted of two lateral fields (in most cases only one field was treated each day) with energies ranging between 225 and 250 MeV. The prescribed dose for protons was 74 CGE at isocenter. A water balloon was inserted in the rectum to maximize target position consistency. With a median follow-up time of 62 months, the overall 5 and 8 years bNED rates were 75 and 73%, respectively. Acute GI and genitourinary (GU) RTOG grade 3 or higher was o1%. Late RTOG grade 3 morbidity was 1% and grade 4 was 0.2%. No difference in toxicities was observed between those treated with mixed beam vs protons alone. Because of the low incidence of grade 3 and 4 side effects, no statistically significant prognostic variable could be found.
The experience of MGH and Loma Linda University Medical Center in proton-beam irradiation of prostate cancer led to the activation of a cooperative phase III study (PROG 95-09). 5 Patients with early stage disease were randomized to receive an initial proton boost dose of 19.8 vs 28.8 CGE, followed by 50.4 Gy photons. At 5 years, bNED was 61.4 and 80.4% for the conventional and the high-dose levels, respectively. Only 2% of patients in the conventional dose and 1% in the high dose experienced RTOG acute grade 3 or higher urinary or rectal morbidity. Late RTOG grade 2 GI morbidity was 8% for the conventional dose and 17% for the high-dose level (P ¼ 0.005).
Although this trial validates the principle of dose escalation and the feasibility of high-dose proton-beam radiotherapy in prostate cancer, it was not designed to test whether this modality is more efficacious or costeffective than other more readily available techniques such as IMRT. 13 A new dose escalation phase I/II dose escalation trial using 84.6 Gy with protons alone for early prostate cancer is now underway by the same two institutions. The lack of comparison with photon-based IMRT will not resolve the issue of whether conventional proton-beam offers a measurable benefit over conventional photon irradiation.
The physical properties of protons may be exploited even more advantageously if modulation of the beam intensities can be realized. Indeed, a great deal of interest surrounds the field of intensity modulated proton therapy (IMPT), whose aim is to deliver complex proton fluence maps from each incident field direction, providing many more degrees of freedom than photon-based IMRT or conventional proton therapy techniques. Potentially, IMPT has the ability to better 'sculpt' the dose to the target and therefore achieve improved critical structure avoidance. This increased target conformality may reduce the sensitivity of the plans to potential delivery errors. The concept of IMPT as a tool for generating treatment plans is only just beginning to be explored, and has not yet been implemented clinically. In a model study, Yeboah et al. 29 found that using IMPT beams for inverse planning instead of IMRT beams, improved target dose homogeneity by up to 1.3% of the prescribed target dose, while reducing the mean rectal dose, bladder dose and normal tissue integral dose by up to 27, 30 and 28% of the prescribed target dose, respectively. Cella et al. 30 compared several treatment plans including IMPT and IMRT for a prescription dose of 81 Gy. Both techniques turned out to be successful in achieving target coverage while complying with the dose/volume constraints for the organs at risk. IMRT, however, exposed nontarget tissues to a 1.7-fold increase in dose compared to IMPT. When the target dose was escalated from 81 to 99 Gy no additional reduction in dose homogeneity with IMRT compared to IMPT was observed, and the dose-volume histograms for the rectum remained very similar between the two plans. In addition, no increase in the ratio between the integral dose of the two techniques was observed as a consequence of this escalation.
The main advantage of IMPT, therefore, consists in a significant reduction in the low to medium doses delivered to nontarget tissues, which could translate into a theoretically reduced risk of radiation-induced malignancies. With scanning proton beams, however, other theoretical advantages may come into play. Traditionally, for clinical purposes proton beams are assumed to have a fixed overall RBE of 1.1. However, it is well known that the RBE increases with depth in the SOBP and becomes about 10% higher than mid-SOBP RBE at 2 mm from the distal edge 31 and can reach values of up to 1.4 in vitro at the distal edge. 32 It has been suggested that RBE variations be incorporated into the 33 Such a correction in clinical proton therapy planning may minimize potentially harmful effects on sensitive healthy tissues immediately adjacent to the target volume.
High-LET radiation: neutrons
Large experience with high LET radiation therapy in prostate cancer is limited to neutron therapy. Indeed, a higher RBE offers potential radiobiological benefits in slow-growing and radio-resistant tumors. However, the RBE of neutrons compared to X-rays is difficult to calculate (range 2-5) as it significantly varies with neutron-beam energy and dose. Historical experience with neutrons in prostate cancer is extensive and has invariably shown improved outcomes compared to conventional standard dose photon radiotherapy. An RTOG-randomized clinical trial (77-04) 34 compared mixed neutron and photons (felt to be equivalent to 70 Gy in 7 weeks) to conventional photons only (70 Gy in 7 weeks) in patients with locally advanced prostate cancer. An advantage with neutrons was found both in terms of local control (85 and 62% at 5 years and 70 and 58% at 10 years, respectively) and of overall survival (70 and 53% at 5 years and 46 and 29% at 10 years, respectively). However, the neutron arm showed an unacceptably high RTOG grade X3 morbidity (24% in the mixed neutron arm vs 8% in the photon arm) including musculoskeletal toxicity resulting in hip stiffness.
A subsequent randomized trial 35 compared 100% fast neutrons (20.4 nGy in 12 fractions over 4 weeks) to conventional photon therapy (70 Gy standard fractionation) in 178 patients with stage T2-T4 prostate cancer. The study confirmed an improvement in local control rates and biochemical-free survival with neutrons, which, did not, however, translate into improved overall survival. Morbidity was significantly higher in the neutron arm with 11% grade 3-4 toxicity vs 3% in the photon arm. The complication rates in the neutron arm, however, were inversely correlated with the degree of neutron beam shaping available at the participating institutions. 36, 37 A European mixed neutron/photon beam experience has been recently reported. 38 All patients were treated with a mixed photon/neutron irradiation in a two-tothree proportion, up to a total equivalent dose of 66 Gy (assuming a clinical RBE value of 2.8). Pre-and posttreatment PSA determinations were available in practically all cases. With a median follow-up of 2.8 years, the 5-year overall survival was 79% and the biochemical progression-free survival was 64% for the entire series. The morbidity associated with this treatment approach was investigated using the European Organization for Research and Treatment of Cancer validated QLQ-C30 questionnaire in 230 patients who had been treated with various neutron/photon ratios. 39 Overall, the treatment approach used was considered to adversely impact on the quality of life (QOL) of the patients. Patients scored their overall physical condition as a mean score of 5.2 and overall QOL as a mean of 5.3 on a 7-point scale. A significant correlation between greater neutron/photon ratios and the occurrence of bowel problems was observed, with 34% of patients treated with X60% of neutrons experiencing difficulties in retaining stools.
Because of the high rate of adverse effects seen with neutrons most studies were discontinued. At Wayne State University in Detroit, however, the development of a state-of-the-art equipment (rotating gantry, multirod collimator, 3D-treatment planning) allowed the implementations of a new series of phase II trials to establish the optimal mixture of neutrons and photons. 40 A mixture of 10 nGy plus 38-40 Gy delivered with 3D-CRT was found to be extremely well tolerated. Another aspect that was investigated on was whether the sequence of the two treatments was of importance. 41 Preclinical data had shown that a therapeutic gain could be achieved when neutron irradiation was used first rather than following photon irradiation. 42 The interpretation of this sequence effect is difficult, but it may be attributed to the greater efficacy of neutrons on hypoxic cells and to the increased presence of intracellular oxygen following tumor changes induced by neutron irradiation. Patients with organconfined disease, therefore, were randomized in a phase III study to receive either neutrons first followed by 3D-CRT or vice versa. There was no difference in the rate of complications between the two groups. At 5 years the overall disease-free survival for the patients treated with neutron first was 93% compared to 73% for those treated with photons first (P ¼ 0.008).
To answer the question of whether there was an ideal patient population that would most benefit from neutron irradiation, a matched-pair retrospective analysis between mixed beam and photon irradiation only was performed. The following risk factors were considered in the analysis: cT3; GPS 47; iPSA 410 ng/ml. For patients with no risk factors, disease-free survival with or without neutron irradiation was 88 vs 89%, respectively (P ¼ 0.8). However, for patients with one adverse risk factor, disease-free survival was 78 vs 53% (P ¼ 0.01), for two risk factors 59 vs 47% (P ¼ 0.06) and 36 vs 7% (P ¼ 0.0004) for patients with all three risk factors present. Based on the results of this study, patients with no adverse risk factors do not benefit from high-LET irradiation. 40 Despite the encouraging outcomes and reduced treatment-related morbidity reported from Wayne State University, clinical use of neutrons in prostate cancer has been largely discontinued. One contributing factor is the theoretical increase in the risk of second malignancies due to the higher RBE of neutrons and unimproved dose distributions and integral doses compared to photons. In fact, dose escalation with photons has been shown to yield outstanding biochemical control rates in all risk categories, and is associated with minimal treatmentrelated late toxicity when delivered with high-precision techniques.
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High-LET radiation: light ions
Like neutrons, light ions, such as neon and carbon ions, have a significantly higher RBE than photons, but due to their prominent Bragg peak display exquisite dose distributions, similar to those of protons. The improved dose distributions to nontarget tissues may result in significantly lower normal tissue complication probabilities, and reduced risk of radiation-induced malignancies compared to neutrons.
Particle therapy in prostate cancer C Greco
Historical data on the use of neon ions in prostate radiotherapy come from Berkeley. 43 Twelve patients with locally advanced prostate cancer were treated with a combined pelvic conventional photon irradiation followed by a neon particle boost. Physical neon beam doses ranged between 10 and 14 GyE (RBE 2.38). Total radiation doses ranged between 70 and 79.2 GyE. Local control and overall survival rate at 5 years were 75 and 90%, respectively. One patient developed severe radiation proctitis requiring a colostomy following a total radiation dose of 79 GyE (X-ray dose 50.4 Gy, neon dose 12 GyE).
Unfortunately, operations at the Berkeley Laboratory were stopped in 1992 for budget reasons. The modern literature on light ions in prostate cancer is scarce and, to date, comes exclusively form Japanese experiences.
A phase I/II dose escalation trial in T1b-T3 prostate cancer treated exclusively with carbon ions has recently been reported from Chiba. 19 Treatment schedule was 20 fractions 5 days a week with doses gradually increased from 54 to 72 GyE in 10% increments. Dose expressed in GyE is the product of the carbon ion physical dose and the RBE value of 3.0. 24 A total of 96 patients were accrued in this study. No patients presented grade 3 acute morbidity. Grade 3 late morbidity developed in one patient treated to 66 GyE and in five treated to 72 GyE. Total dose was therefore set to 66 Gy, and a cone-down excluding the anterior wall of the rectum was performed beyond 50 GyE. A 5% decrease in dose was required for diabetic patients to reduce the risk of side effects. Local control was observed in all but one patient treated to a dose of 54 GyE. At 5 years, bNED according to the American Society for Therapeutic Radiology and Oncology definition was 82.6%, while overall and causespecific survival rates were 97.7 and 94.9%, respectively. All patients with favorable prognostic factors were all free from biochemical recurrence at 5 years. Patients in the high-risk group (T2b-T3, GPSX7 or PSAX20 ng/ml) had a bNED of 81.1%.
Analysis of the long-term outcome and toxicity data in a large group of patients treated with carbon-ion therapy at the recommended dose of 66 GyE has been reported recently. 20 No grade X3 toxicities were observed. The incidence of grade 2 late rectal toxicity was 1% and the incidence of GU late grade 2 toxicity was 6%. The outstanding toxicity profile reported in this study was largely attributed to the favorable characteristics of carbon-ion beams in terms of dose conformity. Overall, 5-year freedom from biochemical failure was 83.2%. Gleason score, initial PSA and T stage were all independent predictors of bNED. Patients with initial PSA p20 ng/ml and GPS p7 had a 5-year bNED of 97.1%. In light of the favorable outcome with the adopted fractionation scheme and minimal rate of late morbidity, the use of higher dose per fraction is currently under consideration. 20 Indeed, carbon-ion data compare favorably with published results for equivalent doses with Xrays, and in fact, the RBE for carbon ions may exceed 3.0. 24 The effect of alterations in dose fractionation schedule for charged particles is difficult to estimate. With the arbitrary assumption that the linear quadratic model may be applied to carbon ions similarly to photons, the BED of total dose of 66 GyE in 20 fractions would be equivalent to a normalized total dose of 90.5 Gy at 2 Gy fractions with a a/b of 1.5.
A recent update from the Chiba group has confirmed the feasibility and effectiveness of carbon ion therapy in prostate cancer. 22 Late grade 2 GI and GU morbidities were 2 and 5%, respectively. No grade 3 toxicities were observed. Dosimetric analysis revealed that the percentage of rectal volume receiving 50% of the prescribed dose was a predictor of rectal toxicity. 44 In a model study, the Heidelberg group investigated on the therapeutic potential of carbon ion therapy in locally advanced prostate cancer. Due to their sharp dose falloff, carbon-ion plans are particularly sensitive to organ motion and patient positioning uncertainties. Clinical evidence of improved local tumor control in locally advanced prostate cancer with the combination of photons and high LET neutrons is available in the literature. 35, 45, 46 A combination of photon IMRT and carbon-ion boost to the gross tumor volume has thus been recommended as the most rational solution in gaining initial clinical experience before embarking on a full dose with ion beam therapy. 47 The positive results reported from Japan require confirmation from well-designed randomized trials comparing treatment outcomes of carbon ion therapy with those from high-dose proton therapy and state-ofthe-art photon-based IMRT. Assessment instruments sensitive enough to capture other important elements of therapy outcome, such as health-related QOL, ought to be used to appreciate subtle differences between treatment modalities.
Radiation-induced second malignancies
Undoubtedly, diagnosis of prostate cancer at a younger age is not uncommon, with many younger patients opting, or seriously considering, radiation options. With increased effectiveness of high-dose irradiation and long life expectancy, radiation-induced second cancer may become an important concern, especially in this younger patient cohort.
The results of retrospective analysis of epidemiological data of second malignancies in the prostate patient population treated with conventional radiation are difficult to interpret due to the presence of inherent confounding factors. Some studies indicate no increased risk of second cancers, 48, 49 whereas others have shown a significant association between prostate irradiation and subsequent malignancy. Brenner et al. 50 reported a small but statistically significant increase in the risk of second solid tumors in patients treated with radiation compared to surgery, using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program. The risk of a second cancer of any type was about 6% higher in patients who had received irradiation compared to surgery. The increased relative risk became larger with time and reached 15% at 5 years and 34% at 10 years. In absolute terms, the estimated risk of developing a radiation-induced malignancy was 1 in 290 for all patients treated with radiation, increasing to 1 in 70 patients for the long-term survivors (410 years), or 1.4%.
An increased risk in bladder cancer following external beam irradiation has been confirmed by at least three studies. 51, 52 In a retrospective cohort study, Baxter et al.
53
noted a significant increase in development of rectal
Particle therapy in prostate cancer C Greco cancer in patients managed with radiation compared to surgical patients. A study by Kendal et al. 54 was unable to demonstrate any significant increased incidence of rectal cancer in men irradiated for prostate cancer when age and other possible confounders were accounted for. Several reports on sarcomas following prostate radiotherapy have appeared in the recent literature. [55] [56] [57] Overall, there appears to be sufficient epidemiological evidence to suggest that postirradiation second malignancies do occur, some of which may be fatal for the patient. It is argued that studies that have failed to show an increase in second cancers may have suffered from inherent biases or were lacking in statistical power. 58 In absolute terms, however, the number of second malignancies is relatively low (approximately 1% for longterm survivors, at least with conventional treatment modalities), despite the relatively high hazard ratios reported. 50 Furthermore, with the transition from conventional radiation therapy to 3D-CRT and the consequent reduction in normal tissue exposure, a reduction in the incidence of radiation-induced malignancies may be expected. The higher integral doses to normal tissues often associated with IMRT have received attention as a possible cause of increased risk of second cancer induction. 15 Preliminary calculations for the typical fivefield plan 15 MV 81 Gy prostate IMRT used at Memorial Sloan-Kettering Cancer Center, however, have demonstrated that the improved conformality can lead to integral doses within the irradiated volume that are comparable to a four-field 75.6 Gy conventional external beam arrangement and significantly lower than a sixfield 3D-CRT arrangement. 59 The commensurate decreases in rectal and bladder dose, therefore, may be expected to translate into even further reduction in the incidence of induced malignancies in these organs. The total-body exposure due to leakage of radiation and neutron contamination, however, still poses concerns with IMRT, due to the significantly longer beam-on time. Because of this, Hall and Wuu 15 have predicted an approximately twofold increase of second malignancies in patients surviving 410 years when treated with IMRT. Kry et al. 16 in a model study calculated the risk of fatal secondary malignancies deriving from out-of-field radiation doses to normal tissues for different treatment techniques. The risk estimate was 1.7% for conventional 3D-CRT with 18 MV, 2.1% for IMRT using 10 MV and 5.1% for IMRT using 18 MV, due to the higher neutron contribution at this energy. According to this study, therefore the risk of a fatal second malignancy is three times greater with 18 MV IMRT compared to 18 MV conventional 3D-CRT, but is only slightly increased with 10 MV IMRT. It is argued that, if a high-energy beam confers modest gains in terms of target coverage and normal tissue sparing compared to lower energy beams (6-10 MV), when using IMRT, it may be more advantageous for the patient's long-term health to opt for the latter. 16 Furthermore, some technical measures to mitigate the problem of leakage radiation during IMRT have been proposed, such as increased shielding in the treatment head or the removal of the flattening filter, which is not needed in a linear accelerator dedicated to IMRT. 58 The risk of second malignancy induction is strongly dependent on the RBE of the radiation used. High-LET radiations, therefore, carry a greater risk. After fast neutron therapy, the risk of secondary cancer induction has been estimated to be approximately 10-20 times greater than after photon therapy. 60 Carbon ions have an estimated RBE similar to neutrons but the risk of carcinogenesis associated with their use is estimated to be at least threefold lower as a result of the significant reduction in integral dose. 61 This risk estimate may turn out to be overly pessimistic, since, with carbon ions, most of the normal tissues, at the boundary of the initial plateau, are irradiated with low-LET radiation. 61 To date, however, no reports have substantiated these assumptions.
On theoretical grounds, therefore, proton-beam therapy (RBE 1.1) carries a lower risk (by a factor of 3) of secondary cancer induction relative to photons, due to the reduction of integral dose. It has been pointed out, however, that this benefit can be achieved if a scanning beam is used. In proton facilities in which passive modulation is used to shape a certain field, neutrons are produced, which results in effective dose to the patients significantly higher than that characteristic of an IMRT. 58 
Cost-effectiveness
Proton therapy is more expensive than X-ray radiation therapy 62 by a factor of 1.5-3 with respect to a similar accessory set-up with X-rays. 63, 64 This broad range is a function of several factors including the number of patients treated per year, the number of treatment rooms and the number of gantries. The cost of light ions is estimated to be at least three times higher than that of protons and approximately eight times higher than X-rays. 65 The peer-reviewed literature contains little evidence on the cost-effectiveness of proton or light ion radiotherapy in general. 66, 67 The cost-effectiveness of proton therapy in prostate cancer has been the subject of a Swedish analysis. 68 Based on a series of assumptions (including direct reduced mortality through dose escalation and reduced side effects) proton therapy was deemed cost-effective in prostate cancer patients with longer life expectancy and poorer prognostic factors. 62 In this assessment, however, it was arbitrarily assumed that proton therapy could achieve a 20% reduction in mortality through dose escalation with respect to conventional photon irradiation, neglecting the current evidence that dose escalation to unprecedented dose levels can now be safely accomplished by IMRT. The assumption that an improvement in QOL through reduced treatment-related toxicity can be achieved by proton therapy is still unsubstantiated by valid clinical data. To date, no attempt has been made to compare the cost-effectiveness of current photon-based IMRT and proton treatments based on the available body of outcome and toxicity data from modern published series.
Conclusions
Comparative studies have shown that similar dose distributions, with fulfillment of dose-volume constraints for normal tissues, may be achieved through intensity modulation with X-rays and protons. From a radiobiological standpoint, protons, with their RBE of 1.1, do not provide added clinical advantage, at least to a Particle therapy in prostate cancer C Greco degree that is not achievable through dose escalation with X-rays. The full potential of protons, however, is still to be seen when IMPT becomes a reality and becomes fully implemented clinically. Light ions, while sharing similar physical advantages with protons, also have a theoretical radiobiological advantage deriving from their higher RBE (B3.0), which may turn out to be clinically effective in high-risk, locally-advanced disease. The encouraging preliminary results obtained with carbon ion therapy await confirmation in controlled clinical trials, with particular emphasis on toxicity and health-related QOL issues, comparing light ions to stateof-the-art photon and proton image-guided, intensitymodulated techniques.
